IDSA Releases New Guidelines For COVID-19 Treatment
The guidelines were recently updated to reflect new information on COVID-19 treatment and management.
The guidelines were recently updated to reflect new information on COVID-19 treatment and management.
A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.
Insights from Pranay Sinna MD on a multicenter prospective cohort study on household contacts.
In a collaboration between the University of Oxford, the Ministry of Health in Rwanda, and the Rwanda Biomedical Centre, groundbreaking data on the R21/Matrix-M malaria…
PEN-FAST is a validated risk stratification tool that promotes efficient, safe, and effective de-labeling of penicillin allergies.
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her insights…
Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
FDA recalls, allergy alerts, e coli & salmonella outbreaks, and more.
With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.